Novel tactics for designing water-soluble molecules in drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 12, 2014, Pages 1421-1433

  Walker, Michael A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Aqueous solubility; Crystal packing; Crystalline stability; Drug properties; General solubility equation; Hydration; Hydrophobicity; Melting point; Solvation

Indexed keywords

LIGAND; DRUG; WATER;

ARTICLE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DIASTEREOISOMER; DRUG DEVELOPMENT; DRUG SOLUBILITY; DRUG STABILITY; GENERAL SOLUBILITY EQUATION; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; STEREOCHEMISTRY; THERMODYNAMICS; ALGORITHM; CHEMISTRY; SOLUBILITY;

ALGORITHMS; DRUG DISCOVERY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WATER;

EID: 84912015874     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.960839     Document Type: Article

References (71)

1. Van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-33
2. Oprea TI. Current trends in lead discovery: are we looking for the appropriate properties?. J Comput Aided Mol Des 2002;16:325-34
3. Leeson PD, Springthorpe B. The influence of drug-like concepts on Decision-making in medicinal chemistry. Nat Rev Drug Dis 2007;6:881-90
4. Leeson PD, St-Gallay SA. The influence of the 'organizational factor' on compound quality in Drug discovery. Nat Rev Drug Dis 2011;10:749-65
5. Meanwell NA. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 2011;24:1420-56
6. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
7. Lipinski C, Lombardo F, Dominy B, Feeney P. Experimental and computational approaches to estimate solubility and permeability in Drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
8. Curatolo W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm Sci Technol Today 1998;1:387-93
9. Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
10. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 1996;13:1795-8
11. Stagemann S, Leveiller F, Franchi D, et al. When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 2007;31:249-61
12. Hill AP, Young RJ. Getting physical in Drug discovery: a contemporary perspective on solubility and hydrophobicity. Drug Discov Today 2010;15:648-55
13. Hann MH. Molecular obesity, potency and other addictions in Drug discovery. MedChemComm 2011;2:349-55
14. Zuegg J, Cooper MA. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. Curr Top Med Chem 2012;12:1500-13
15. Di L, Fish PV, Mano T. Bridging solubility between Drug discovery and development. Drug Discov Today 2012;17:486-95
16. Jain N, Yalkowsky SH. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J Pharm Sci 2001;90:234-52
17. Ran Y, He Y, Yang G, et al. Estimation of aqueous solubility of organic compounds by using the general solubility equation. Chemosphere 2002;48:487-509
18. Leo JL, Hansch C. Role of hydrophobic effects in mechanistic QSAR. Perspect Drug Discov 1999;17:1-25
19. Bergstrom CAS, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007;50:5858-62
20. Wassvik CM, Holmen AG, Draheim R, et al. Molecular characteristics for solidstate limited solubility. J Med Chem 2008;51:3035-9
21. Hvidt A. Interactions of water with nonpolar solutes. Ann Rev Biophys Bioeng 1983;12:1-20
22. Lombardo F, Faller B, Shalaeva M, et al. The good, bad and ugly of distribution coefficients: current status, views and outlook. In: Mannhold R, editor. Molecular drug properties. Wiley-VCH; Weinheim: 2008
23. Abraham MH, Chada HS, Whiting GS, Mitchell RC. Hydrogen bonding. 32. An analysis of water-octanol and wateralkane partitioning and the deltalog P parameter of Seiler. J Pharm Sci 1994;83:1085-100
24. Shalaeva M, Caron G, Abramov YA, et al. Integrating intramolecular hydrogen bonding (IMHB) considerations in Drug discovery using deltalogP as a tool. J Med Chem 2013;56:487-4879
25. Morgenthaler M, Schweizer E, Hoffmann-Roder A, et al. Predicting and tuning physicochemical properties in lead optimization: amine basicities. ChemMedChem 2007;2:1100-15
26. Burkhard JA, Wagner B, Fischer H, et al. Synthesis of azaspirocycles and their evaluation in Drug discovery. Angew Chem Int Ed Engl 2010;49:3524-7
27. Laurence C, Brameld KA, Graton J, et al. The pK(BHX) database: toward a better understanding of hydrogen-bond basicity for medicinal chemists. J Med Chem 2009;52:4073-86
28. Zhao F, Lin Z, Wang F, et al. Four-membered heterocycles-containing 4-Anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. Bioorg Med Chem Lett 2013;23:5385-8
29. Addie M, Ballard P, Buttar D, et al. Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7Hpyrrolo[ 2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 2013;56:2059-73
30. Brock CP, Schweizer WB, Dunitz JD. On the validity of Wallach's rule: on the density and stability of racemic crystals compared with the chiral counterparts. J Am Chem Soc 1991;113:9811-20
31. Yang Y, Engkvist O, Llinas A, Chen H. Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds. J Med Chem 2012;55:3667-77
32. Dossetter AG, Griffen EJ, Leach AG. Matched molecular pair analysis in Drug discovery. Drug Discov Today 2013;18:724-31
33. Leach AG, Jones HD, Cosgrove DA, et al. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. J Med Chem 2006;49:6672-82
34. Zhang L, Zhu H, Mathiowetz A, et al. Deep understanding of structuresolubility relationship for a diverse set of organic compounds using matched molecular pairs. Bioorg Med Chem Lett 2011;19:5763-70
35. Gleeson P, Bravi G, Modi S, et al. ADMET rules of thumb II: a comparison of the effects of common substituents on a range of ADMET parameters. Bioorg Med Chem 2009;17:5906-19
36. Barnes-Seeman D, Beck J, Springer C. Fluorinated compounds in medicinal chemistry: recent applications, synthetic advances and matched-pair analyses. Curr Top Med Chem 2014;14:855-64
37. Barreiro EJ, Kummerle AE, Fraga CAM. The methylation effect in medicinal chemistry. Chem Rev 2011;111:5215
38. Kuhn B, Mohr P, Stahl M. Intramolecular hydrogen bonding in medicinal chemistry. J Med Chem 2010;53:2601-11
39. Fujita T, Iwasa I, Hansch C. A new substituent constant, p, derived from partition coefficients. J Am Chem Soc 1964;86:5175-80
40. Hansch C, Quinlan JE, Lawrence GL. The linear free-energy relationship between partition coefficients and the aqueous solubility of organic liquids. J Org Chem 1968;33:347-50
41. Jaysys VJ, Lombardo F, Appleton TA, et al. Preparation of fluoroadamantane acids and amines: impact of bridgehead fluorine substitution on the solution- And solid-state properties of functionalized adamantanes. J Am Chem Soc 2011;122:466-73
42. Atarashi S, Imamura M, Kimura Y, et al. Fluorocyclopropyl quinolones. 1. Synthesis and structure-Activity relationships of 1-(2-fluorocyclopropyl)-3-pyridonecarboxylic acid antibacterial agents. J Med Chem 1993;36:3444-8
43. Wenglowsky S, Moreno D, Rudolph J, et al. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing. Bioorg Med Chem Lett 2012;22:912-15
44. Over B, McCarren P, Artursson P. Impact of stereospecific intramolecular hydrogen bonding on cell permeability and physicochemical properties. J Med Chem 2014;57:2746-54
45. Ritchie TJ, Macdonald SJF. The impact of aromatic ring count on compound developability - Are too many aromatic rings a liability?. Drug Discov Today 2009;24:1011-20
46. Ritchie TJ, Macdonald SJF, Young RJ, Pickett SD. The impact of aromatic ring count on compound developability: further insights by examining carbo- And hetero-Aromatic and -Aliphatic ring types. Drug Discov Today 2011;16:164-71
47. Lovering F, Bikker J, Humblet C. Escape from flatland: increasing saturation as an approach to improving clinical success. J Med Chem 2009;52:6752-6
48. Bradbury RH, Acton DG, Broadbent NL, et al. Discovery of AZD3514, a small-molecule androgen receptor down regulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett 2013;23:1945-8
49. Stepan AF, Subramanyam C, Efremov IV, et al. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active gamma-secretase inhibitor. J Med Chem 2012;55:3414-24
50. Dunitz JD, Filippini G, Gavezzotti A. A statistical study of density and packing variations among crystalline isomers. Tetrahedron 2000;56:6591-601
51. Gavezzotti A, Desiraju GR. A systematic analysis of packing energies and other packing parameters for fused ring aromatic hydrocarbons. Acta Cryst 1988;44:427-34
52. Du Y, Creighton CJ, Tounge BA, Reitz AP. Noncovalent self-Assembly of bicyclo[4.2.2]diketopiperazines: influence of saturation in the bridging carbacyclic ring. Org Lett 2004;6:306-12
53. Chan IYH, Nguyen VT, Bishop R. The design of "awkward" molecules expected to yield multiple crystal forms. Cryst Growth Des 2010;10:4582-9
54. Gavezzotti A. The chemistry of intermolecular bonding: organic crystals, their structures and transformations. Synlett 2002;2:1437-2096
55. Gavezzotti A. A solid-state chemist's view of the crystal polymorphism of organic compounds. J Pharm Sci 2007;96:2232-41
56. Dunitz JD, Gavezzotti A. How molecules stick together in organic crystals: weak intermolecular interactions. Chem Soc Rev 2009;38:2622-33
57. Gavezzotti A. Quantitative ranking of crystal packing modes by systematic calculations of potential energies and vibrational amplitudes or molecular dimers. J Chem Theory Comput 2005;1:834-40
58. Etter MC. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc Chem Res 1990;23:120-6
59. Pinal R. Effect of molecular symmetry on melting temperature and solubility. Org Biomol Chem 2004;2:2692-9
60. Wei J. Molecular symmetry, rotational entropy, and elevated melting points. Ind Eng Chem Res 1999;38:501905027
61. Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem 2011;54:1539-54
62. Li JJ, Sutton JC,Nirschl A. Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications. J Med Chem 2007;50:3015-25
63. Fujita Y, Yonehara M, Kitahara K, et al. Conformation of molecular planarity disruption effect on aqueous solubility improvement of beta-naphthoflavone analogs. Heterocycles 2011;83:2563-75
64. Foote KM, Blades K, Cronin A, et al. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem 2013;56:2125-38
65. Cambridge Crystallographic Data Center deposition number 916869
66. Cambridge Crystallographic Data Centre deposition number 915814
67. Segall MD. Multi-parameter optimization: identifying high quality compounds with a balance of properties. Curr Pharm Des 2012;18:1292-310
68. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-1
69. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today 2005;10:464-9
70. Palucki M, Higgins JD, Kwong E, Templeton AC. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. J Med Chem 2010;53:5897-905
71. Saal C. Optimizing the solubility of research compounds: how to avoid going off track. Am Pharm Rev 2010;13:14-28